Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study);Estudio observacional retrospectivo sobre la efectividad del ácido 5-aminolevulínico en la cirugía de los gliomas malignos en España (Estudio VISIONA)

Neurologia

Volumn 29, Issue 3, 2014, Pages 131-138

  Diez Valle R ^a   Slof, J ^b   Galvan J ^c   Arza, C ^c   Romariz, C ^c   Vidal, C ^d   Valle Dr , Ricardo Díez ^e   i Rodriguez, Pilar Teixidor ^e   Martínez, Gloria Villalba ^e   Cabezudo Dr , Jose Manuel ^e   García Dr , Luis Miguel Bernal ^e   Sánchez Dr , Josep J González ^e   Rodríguez Dr , Enrique Ferrer ^e   Sánchez Dr , Miguel Ángel Arraez ^e   Granados Dr , Gonzalo Olivares ^e   Delgado Dr , Álvaro Toledano ^e   Bertrán Dr , Gerardo Conesa ^e   Martín Dr , Juan José Acebes ^e   Ahicart Dr , Gerard Plans ^e   Díaz Dr , Avelino Parajón ^e   Asunción Dr , Carlos Botella ^e   Acin Dr , Ricardo Prat ^e   de Pedro, Marta del Álamo ^e   Urzaiz Dr , Luis Ley ^e   Barcia Dr , Juan A ^e   Brin Dr , Juan R ^e   Campa Santamarina Dr , José María Torres ^e   Sánchez Dr , Ángel Maíllo ^e   Peña Dr , Jesús Merino ^e   more..

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Gebro Pharma Ltd   (Spain)

^d Needs and Aims   (Spain)

^e NONE

Author keywords

5 aminolevulinic acid; Complete resection; Fluorescence image guided surgery; Glioblastoma; Malignant glioma; Progression free survival

Indexed keywords

AMINOLEVULINIC ACID; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; PHOTOSENSITIZING AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL PRACTICE; DRUG DETERMINATION; DRUG EFFICACY; FUNCTIONAL STATUS; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE PERIOD; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SPAIN; SURVIVAL TIME; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; COMPUTER ASSISTED SURGERY; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; FEMALE; MALE; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PHOTOSENSITIZING AGENTS; RETROSPECTIVE STUDIES; SURGERY, COMPUTER-ASSISTED; TREATMENT OUTCOME;

EID: 84897385412     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2013.05.004     Document Type: Article

References (20)

1. Stummer W., Reulen H.J., Meinel T., Pichlmeier U., Schumacher W., Tonn J.C., et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 2008, 62:564-576. [discussion 564-576].
2. Sanai N., Polley M.Y., McDermott M.W., Parsa A.T., Berger M.S. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011, 115:3-8.
3. Lacroix M., Abi-Said D., Fourney D.R., Gokaslan Z., Shi W., DeMonte F., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001, 95:190-198.
4. Sanai N., Berger M.S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62:753-764. [discussion 264-6].
5. Albert F.K.M.D., Forsting M.M.D., Sartor K.M.D., Adams H.D.I.M., Kunze S.M.D. Early postoperative magnetic resonance imaging after resection of malignant glioma: Objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994, 34:45-61.
6. Stummer W., Stocker S., Wagner S., Stepp H., Fritsch C., Goetz C., et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998, 42:518-525. [discussion 525-6].
7. Stummer W., Pichlmeier U., Meinel T., Wiestler O., Zanella F., Reulen H.J., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase iii trial. Lancet Oncol 2006, 7:392-401.
8. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
9. Macdonald D.R., Cascino T.L., Schold S.C., Cairncross J.G. Response criteria for phase iistudies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
10. Diez Valle R., Tejada Solis S., Idoate Gastearena M.A., Garcia de Eulate R., Dominguez Echavarri P., Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: Volumetric analysis of extent of resection in single-center experience. J Neurooncol 2011, 102:105-113.
11. Schucht P., Beck J., Abu-Isa J., Andereggen L., Murek M., Seidel K., et al. Gross total resection rates in contemporary glioblastoma surgery: Results of an institutional protocol combining 5-aminolevulinic acid intraoperative fluorescence imaging and brain mapping. Neurosurgery 2012, 71:927-936.
12. Hefti M., von Campe G., Moschopulos M., Siegner A., Looser H., Landolt H. 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: A one-year experience at a single institutuion. Swiss Med Wkly 2008, 138:180-185.
13. Nabavi A., Thurm H., Zountsas B., Pietsch T., Lanfermann H., Pichlmeier U., et al. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: A phase ii study. Neurosurgery 2009, 65:1070-1076. [discussion 1076-7].
14. Roberts D.W., Valdes P.A., Harris B.T., Fontaine K., Hartov A., Fan X., et al. Coregistered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin ix fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters. Clinical article. J Neurosurg 2011, 114:595-603.
15. Stummer W., van den Bent M.J., Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: New arguments in an old discussion. Acta Neurochir (Wien) 2011, 153:1211-1218.
16. Stummer W., Novotny A., Stepp H., Goetz C., Bise K., Reulen H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000, 93:1003-1013.
17. Idoate M.A., Diez Valle R., Echeveste J., Tejada S. Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology 2011, 31:575-582.
18. Valdes P.A., Kim A., Brantsch M., Niu C., Moses Z., Tosteson T., et al. Delta-aminolevulinic acid-induced protoporphyrin ix concentration correlates with histopathologic markers of malignancy in human gliomas: The need for quantitative fluorescence-guided resection to identify regions of increasing malignancy. Neuro Oncol 2011, 13:846-856.
19. Feigl G.C., Ritz R., Moraes M., Klein J., Ramina K., Gharabaghi A., et al. Resection of malignant brain tumors in eloquent cortical areas: A new multimodal approach combining 5-aminolevulinic acid and intraoperative monitoring. J Neurosurg 2010, 113:352-357.
20. Stummer W., Tonn J.C., Mehdorn H.M., Nestler U., Franz K., Goetz C., et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg 2011, 114:613-623.